ASSESSMENT OF ANTICOAGULATION USING ACTIVATED CLOTTING TIME (ACT) IN PATIENTS RECEIVING ENOXAPARIN AND HEPARIN DURING PERCUTANEOUS CORONARY INTERVENTION (PCI).
Keywords:Keywords: ACT (activated clotting time), enoxaparin, heparin, percutaneous coronary intervention (PCI).
Introduction: The standard of therapy for some patients with coronary artery disease,
particularly those who arrive with acute coronary syndrome, is percutaneous coronary
intervention (PCI) (ACS). To avoid thrombotic problems during PCI, the American College of
Cardiology (ACC) and the European Society of Cardiology (ESC) advise using anticoagulation
in addition to dual antiplatelet treatment (DAPT). Objective: to assess how enoxaparin affects
the active clotting time (ACT) and how UFH reacts to enoxaparin. Material and methods: The
intervention cardiology department at Hayatabad Hospital Complex in Peshawar did this crosssectional descriptive research from June 1 to April 30, 2022. By using a non-probability
sequential sampling strategy, patients were included. After a thorough history, examination, and
informed permission, all patients 18 years old having PCI were included in the research.
Individuals with known blood dyscrasias or thrombophilia, as well as those who had received
anticoagulation within the previous 12 hours or just prior, were excluded from the trial. Results:
Among the patients who received heparin, ACT increased from 104.76±27.31 seconds to
448.34±169.11 (t-statistic=13.750, 95% CI: 293.9540 to 393.2060, p: <0.01) whereas among
patients who received enoxaparin, this number increased from 99.58±27.68 seconds to
334.37±166.45 seconds (t statistic=6.817, 95% CI: 165.4597 to 304.1203, p:<0.01). The postanticoagulation ACT was significantly higher in the heparin group compared to enoxaparin
group i.e. 448.34±169.11 and 334.37±166.45 seconds respectively (t statistic=2.700, 95% CI:
29.7639 to 198.1661, p:<0.01). Conclusion: After taking i.v. enoxaparin and heparin, the ACT is
extended in patients for around 15 minutes, and this prolongation may help track the
anticoagulant action of the medication. Moreover, in this situation, ACT levels and ENOX
clotting times are correlated. A bigger experiment will be necessary to determine the association
between ACT level and clinical effectiveness utilising intravenous enoxaparin.
How to Cite
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.